European Non-Polio Enterovirus Network: Introduction of Hospital-Based Surveillance Network to Understand the True Disease Burden of Non-Polio Enterovirus and Parechovirus Infections in Europe.
disease burden
emerging
non-polio enteroviruses
surveillance
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
27 Aug 2021
27 Aug 2021
Historique:
received:
21
06
2021
revised:
18
08
2021
accepted:
25
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Non-polio enteroviruses (EVs) and human parechoviruses (PeVs) cause a wide range of human infections. Limited data on their true disease burden exist as standardized European-wide surveillance is lacking. Our aim is to estimate the disease burden of EV and PeV infections in Europe via establishment of standardized surveillance for hand, foot and mouth disease (HFMD) and respiratory and neurological infections caused by these viruses. We will also assess the sensitivity of assays implemented in the network of participating laboratories so that all EV and PeV types are adequately detected. Plan. The European Non-Polio Enterovirus Network (ENPEN) has developed standardized protocols for a prospective, multi-center and cross-sectional hospital-based pilot study. Protocols include guidance for diagnosis, case definition, detection, characterization and reporting of EV and PeV infections associated with HFMD and respiratory and neurological diseases. Over 30 sites from 17 European countries have already registered to this one pilot study, likely to be commenced in 2022. This surveillance will allow European-wide comparison of data on EV and PeV infection. These data will also be used to determine the burden of EV and PeV infections, which is needed to guide the further prevention measures and policies.
Sections du résumé
BACKGROUND
BACKGROUND
Non-polio enteroviruses (EVs) and human parechoviruses (PeVs) cause a wide range of human infections. Limited data on their true disease burden exist as standardized European-wide surveillance is lacking.
AIMS
OBJECTIVE
Our aim is to estimate the disease burden of EV and PeV infections in Europe via establishment of standardized surveillance for hand, foot and mouth disease (HFMD) and respiratory and neurological infections caused by these viruses. We will also assess the sensitivity of assays implemented in the network of participating laboratories so that all EV and PeV types are adequately detected. Plan. The European Non-Polio Enterovirus Network (ENPEN) has developed standardized protocols for a prospective, multi-center and cross-sectional hospital-based pilot study. Protocols include guidance for diagnosis, case definition, detection, characterization and reporting of EV and PeV infections associated with HFMD and respiratory and neurological diseases. Over 30 sites from 17 European countries have already registered to this one pilot study, likely to be commenced in 2022.
BENEFITS
RESULTS
This surveillance will allow European-wide comparison of data on EV and PeV infection. These data will also be used to determine the burden of EV and PeV infections, which is needed to guide the further prevention measures and policies.
Identifiants
pubmed: 34576722
pii: microorganisms9091827
doi: 10.3390/microorganisms9091827
pmc: PMC8469463
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Euro Surveill. 2018 Nov;23(46):
pubmed: 30458915
Euro Surveill. 2017 Nov;22(45):
pubmed: 29162204
J Infect Dis. 2009 Jun 15;199(12):1753-60
pubmed: 19456229
Euro Surveill. 2015;20(34):30005
pubmed: 26530407
Virology. 2012 Feb 5;423(1):49-57
pubmed: 22177700
J Clin Virol. 2009 May;45(1):1-9
pubmed: 19372062
J Clin Virol. 2015 Oct;71:1-9
pubmed: 26364237
Emerg Infect Dis. 2019 Mar;25(3):585-588
pubmed: 30789123
Emerg Infect Dis. 2016 Aug;22(8):1387-94
pubmed: 27434186
Euro Surveill. 2014 Mar 27;19(12):20745
pubmed: 24698138
Emerg Infect Dis. 2009 Sep;15(9):1485-8
pubmed: 19788821
Pediatr Infect Dis J. 2019 Jan;38(1):16-21
pubmed: 30234793
J Clin Virol. 2016 Nov;84:90-95
pubmed: 27771495
Lancet Infect Dis. 2010 Nov;10(11):778-90
pubmed: 20961813
Lancet Infect Dis. 2020 Mar;20(3):350-361
pubmed: 31870905
Euro Surveill. 2016 Nov 17;21(46):
pubmed: 27918268
Clin Microbiol Infect. 2017 Nov;23(11):874-881
pubmed: 28344164
Clin Infect Dis. 2008 Aug 1;47(3):358-63
pubmed: 18558876
Emerg Infect Dis. 2021 Jun;27(6):1616-1626
pubmed: 34013874
Lancet Infect Dis. 2016 Nov;16(11):1279-1287
pubmed: 27527749
Front Microbiol. 2018 Mar 29;9:557
pubmed: 29651274
MMWR Morb Mortal Wkly Rep. 2018 May 11;67(18):515-518
pubmed: 29746455
Curr Infect Dis Rep. 2016 Nov;18(11):35
pubmed: 27686677
Emerg Infect Dis. 2019 Jun;25(6):1200-1203
pubmed: 30855226
Euro Surveill. 2019 Aug;24(35):
pubmed: 31481149
Lancet Infect Dis. 2014 Apr;14(4):308-318
pubmed: 24485991
Euro Surveill. 2018 Nov;23(44):
pubmed: 30401013
J Clin Virol. 2018 Apr;101:11-17
pubmed: 29414181
Euro Surveill. 2019 Feb;24(7):
pubmed: 30782267
Emerg Infect Dis. 2016 Nov;22(11):1884-1893
pubmed: 27767012
J Med Virol. 2020 Aug;92(8):1065-1074
pubmed: 31883139
J Virol. 2010 Sep;84(18):9292-300
pubmed: 20610722
J Clin Microbiol. 2013 Nov;51(11):3560-6
pubmed: 23966496